Transjugular intrahepatic portosystemic shunt in the management of complications of portal hypertension

Current Gastroenterology Reports

Volumn 10, Issue 1, 2008, Pages 30-35

  Boyer, Thomas D ^a  

^a AHSC 245136   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; ASCITES; BRAIN DISEASE; BUDD CHIARI SYNDROME; ESOPHAGUS HEMORRHAGE; ESOPHAGUS VARICES BLEEDING; FISTULA; HEMOBILIA; HEMOLYSIS; HEPATORENAL SYNDROME; HUMAN; HYDROTHORAX; INFECTION; LIVER CIRRHOSIS; OCCLUSION; PARACENTESIS; PORTAL HYPERTENSION; PREDICTION; RECURRENT DISEASE; REVIEW; SEPSIS; STOMACH DISEASE; STOMACH VARICES; SURGICAL APPROACH; SURVIVAL; THROMBOSIS; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; ARTICLE;

HUMANS; HYPERTENSION, PORTAL; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC;

EID: 49149119473     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-008-0006-y     Document Type: Review

References (41)

1. Groszmann R, Garcia-Tsao G, Bosch J, et al.: Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005, 353: 2254-2261.
2. Stokkeland K, Brandt L, Ekbom A, Hultcrantz R: Improved prognosis for patients hospitalized with esophageal varices in Sweden 1969-2002. Hepatology 2006, 43: 500-505.
3. Boyer TD, Haskel Z: The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension Hepatology 2005, 41: 386-400.
4. Chalasani N, Clark WS, Martin LG, et al.: Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting. Gastroenterology 2000, 118: 138-144.
5. Malinchoc M, Kamath PS, Gordon FD, et al.: A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000, 31: 864-871.
6. Schepke M, Roth F, Fimmers R, et al.: Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. Am J Gastroenterol 2003, 98: 1167-1174.
7. Bureau C, Pagan JC, Layrargues GP et al.: Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: Long-term results of a randomized multicenter study. Liver Int 2007, 27: 742-747.
8. Riggio O, Masini A, Efrati C, et al.: Pharmacological prophylaxis of hepatic encephalopathy after transjugular portosystemic shunt: A randomized controlled study. J Hepatol 2005, 42: 674-679.
9. Monescillo A, Martinez-Lagares F, Ruiz del Arbol L, et al.: Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004, 40: 793-801.
10. Vangeli M, Patch D, Burroughs AK: Salvage tips for uncontrolled variceal bleeding. J Hepatol 2003, 37: 703-704.
11. Chau TN, Patch D, Chan YW, et al.: "Salvage" transjugular intrahepatic portosystemic shunts: Gastric fundal compared with esophageal variceal bleeding. Gastroenterology 1998, 114: 981-987.
12. Tripathi D, Therapondos G, Jackson D, et al.: The role of the transjugular intrahepatic portosystemic stent shunt (TIPSS) in the management of bleeding gastric varices: Clinical and haemodynamic correlations. Gut 2002, 51: 270-274.
13. Sharara AI, Rockey DC: Gastroesophageal variceal hemorrhage. N Engl J Med 2001, 345: 669-681.
14. Papatheodoridis GV, Goulis J, Leandro G, et al.: Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis. Hepatology 1999, 30: 612-622.
15. D'Amico G, Pagliaro L, Bosch J: Ahe treatment of portal hypertension: a meta-analytic review. Hepatology 1995, 22: 332-353.
16. Burroughs AK, Vangeli M: Transjugular intrahepatic portosystemic shunt versus endoscopic therapy: Randomized trials for secondary prophylaxis of variceal bleeding: An updated meta-analysis. Scand J Gastroenterol 2002, 249-252.
17. Henderson JM, Boyer TD, Kutner MH, et al.: Distal splenorenal shunt versus transjugular intrahepatic portal systemic shunt for variceal bleeding: A randomized trial. Gastroenterology 2006, 130: 1643-1651.
18. Boyer TD, Henderson JM, Heerey A, et al.: Cost of transjugular intrahepatic portal systemic shunt vs. distal splenorenal shunt in the prevention of variceal rebleeding. J Hepatol 2007, [In press].
19. Russo MW, Zacks SL, Sandler RS, Brown RS: Cost effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding. Hepatology 2000, 31: 358-363.
20. Rubenstein JH, Eisen GM, Inadomi JM: A cost-utility analysis of secondary prophylaxis for variceal hemorrhage. Am J Gastroenterol 2004, 99: 1274-1288.
21. Gralnek IM, Jensen DM, Kovacs TO, et al.: The economic impact of esophageal variceal hemorrhage: Cost effectiveness implications of endoscopic therapy. Hepatology 1999, 29: 44-50.
22. Burak KW, Lee SS, Beck PL: Portal hypertensive gastropathy and gastric vascular ectasia (GAVE) syndrome. Gut 2001, 49: 866-872.
23. Kamath PS, Lacerda M, Ahlquist DA, et al.: Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis. Gastroenterology 2000, 118: 905-911.
24. Urata J, Yamashita Y, Tsuchigame T, et al.: The effects of transjugular intrahepatic portosystemic shunt on portal hypertensive gastropathy. J Gastroenterol Hepatol 1998, 13: 977-979.
25. Ginès P, Cárdenas A, Arroyo V, Rodes J: Management of cirrhosis and ascites. N Engl J Med 2004, 350: 1646-1654.
26. Runyon BA: Management of adult patients with ascites due to cirrhosis. Hepatology 2004, 39: 841-856.
27. Garcia-Tsao G: Ascites. In Zakim and Boyer's Hepatology: A Textbook of Liver Disease, 5th edn. Edited by Boyer TD, Wright TL, Manns MP. Philadelphia: W.B. Saunders; 2006: 333-346.
28. Albillos A, Bañares R, González M, et al.: A meta-analysis of transjugular portosystemic shunt versus paracentesis for refractory ascites. J Hepatol 2005, 43: 990-996.
29. Sanyal A, Genning C, Reddy KR, et al.: The North American study for the treatment of refractory ascites. Gastroenterology 2003, 124: 634-631.
30. Salerno F, Camma C, Enea M, et al.: Transjugular intrahepatic portosystemic shunt for refractory ascites: A meta-analysis of individual patients. Gastroenterology 2007, 133: 825-834.
31. Strauss RM, Martin LG, Kaufman SL, Boyer TD: Transjugular intrahepatic portal systemic shunt (TIPS) for the management of symptomatic cirrhotic hydrothorax. Am J Gastroenterol 1994, 89: 1520-1522.
32. Gordon FD, Anastopoulos HT, Crenshaw W, et al.: The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology 1997, 25: 1366-1369.
33. Siegerstetter V, Deibert P, Ochs A, et al.: Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients. Eur J Gastroenterol Hepatol 2001, 13: 529-534.
34. Arroyo V, Guevara M, Ginès P: Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002, 122: 1658-1676.
35. Martin PY, Ginès P, Schrier RW: Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998, 339: 533-541.
36. Sanyal A, Boyer T, Garcia-Tsao G, et al.: A prospective randomized, double blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology 2006, 44(Suppl 1): 694A.
37. Wong F, Sniderman K, Liu P, et al.: Transjugular intrahepatic portosystemic stent shunt: Effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med 1995, 122: 816-822.
38. Guevara M, Ginès P, Bandi JC, et al.: Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems. Hepatology 1998, 28: 416-422.
39. Olliff SP: Transjugular intrahepatic portosystemic shunt in the management of Budd Chiari syndrome. Eur J Gastroenterol Hepatol 2006, 18: 1151-1154.
40. Gandini R, Konda D, Simonette G: Transjugular intrahepatic portosystemic shunt patency and clinical outcome in patients with Budd-Chiari syndrome: Covered versus uncovered stents. Radiology 2006, 241: 298-305.
41. Fried MW, Connaghan DB, Sharma S, et al.: Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation. Hepatology 1996, 24: 588-591.